MSN Home  |  My MSN  |  Hotmail
Sign in to Windows Live ID Web Search:   
go to MSNGroups 
Free Forum Hosting
 
Important Announcement Important Announcement
The MSN Groups service will close in February 2009. You can move your group to Multiply, MSN’s partner for online groups. Learn More
A Peaceful Place[email protected] 
  
What's New
  
  �?•�?·´`·.·�? �?/A>  
  Copyrights  
  Disclaimer  
  �?•�?·´`·.·�? �?/A>  
  Messages  
  General  
  Articles - Misc.  
  ADHD,ADD, Autism  
  �?Allergies �?/A>  
  Alternative & +  
  § Arthritis §  
  Depression  
  �?Diet �?/A>  
  �?Exercise �?/A>  
  Eyes  
  Fitness and Exercise  
  �? FM & CF �?/A>  
  Headaches  
  Herbs etc  
  IBS & Other DD's  
  �?•�?·´`·.·�?�?/A>  
  Liver  
  Lung Health  
  MS �?/A>  
  ◄Mycoplasms�?/A>  
  Osteoporosis  
  Pain-Coping  
  Skin Disorders  
  Sleep  
  �?Supplements  
  �?Toxins �?/A>  
  Humor �?/A>  
  Household ☼¿☼  
  Mind-Body-Spirit  
  Pictures  
    
  �?Links �?/A>  
  Snags  
  Sources & Resources  
  ≈☆≈E-Cards ≈☆�?/A>  
  Pesticides Exp  
  �?Organic Living  
  Organic Gardens  
  See the Most Recent Posts  
  
  
  Tools  
 
Pain-Coping : Found: Pain Perception Gene
Choose another message board
 
     
Reply
 Message 1 of 2 in Discussion 
From: Rene  (Original Message)Sent: 1/11/2007 10:21 PM


 Pain Perception Gene Is Found
By N WADE

December 14, 2006:- Geneticists following up the case of a 10-year-old Pakistani boy who could walk on coals without discomfort have discovered a gene that is central to the perception of pain.

A mutation in the gene knocks out all perception of injury, raising hopes of developing novel drugs that would abolish pain by blocking the gene’s function.

The boy lived in Lahore and was well known to the city’s medical authorities because he would come to the clinic asking to be patched up after his street performances. To earn money he would pass knives through his arms and walk on burning coals without feeling pain.

A research team led by C. Geoffrey Woods, a physician at the Cambridge Institute for Medical Research in Cambridge, England, reports in today’s Nature that they have identified a genetic defect in some of the boy’s relatives who are also unable to feel pain. The defect inactivates a gene that is critical to the body’s perception of pain. The gene presents an attractive target for drug developers seeking to eliminate pain.

Dr. Allan Basbaum, an expert on pain at the University of California, San Francisco, said the finding was “a very exciting story,�?providing strong proof of the principle that inhibition of the gene “can result in powerful pain control with minimal side effects.�?/FONT>

But if drugs can be developed, Dr. Basbaum said, they should not eliminate pain altogether because of its protective effects.

Dr. Woods, who has patients among the Pakistani emigrant community in Britain, said yesterday that he was told of the boy in one of his periodic visits to Pakistan. He decided to examine him on a later visit, he said, but learned that the boy had died after jumping off the roof of a house to impress his friends.

Dr. Woods then looked to see if there were any other pain-free individuals in the Qureshi clan to which the boy belonged. The clans, now Muslim, are historical remnants of the Hindu caste system, and the people in a clan are often closely related.

After much effort, Dr. Woods and colleagues in Pakistan and Britain eventually found three Qureshi families among whom six members reported that they had never experienced pain in any part of their body.

“None knew what pain felt like, although the older individuals realized what actions should elicit pain,�?the researchers write. Children who do not feel pain soon realize they are regarded as peculiar and learn to simulate it when it would be expected, like after tackles on the football field, Dr. Woods said.

After six years of work, Dr. Woods found that the affected members of all three families had a defect in a gene known as sodium channel N9A, or SCN9A, one of a family of 11 human genes whose protein products govern the initiation of signals that nerves send in the body. They open channels that let sodium ions rush across a nerve cell’s membrane.

The SCN9A gene is active both in nerves that mediate pain and in those of the sympathetic nervous system, which controls vital bodily functions like heart rate. But for reasons that are not yet understood, the affected members of the Pakistani families had no symptoms of a disordered sympathetic nervous system, like irregular heart rate, and seemed entirely normal apart from the occasional self-inflicted damage caused by their inability to feel pain. Several had inadvertently bitten off the tips of their tongues in infancy.

Dr. Woods’s discovery “is an important part of a fascinating story,�?said Dr. Stephen G. Waxman, a neurologist at Yale University who studies erythromelalgia, a disease in which patients feel an intense burning sensation after exposure to mild warmth. This disease is also caused by mutations in the SCN9A gene, but ones that enhance the gene’s activity instead of blocking it.

Drug developers might find the gene particularly interesting because the defective form in the Pakistani patients seems to have no side effects, even in the sympathetic nervous system where they would be expected, Dr. Waxman said. “But having a target doesn’t guarantee that drugs can be developed,�?he said.


Dr. Woods said he believed that the Qureshi boy in Lahore whose exploits stimulated his research would have had a defective SCN9A gene. The boy’s mother had one defective copy of the gene, as presumably did his father, a first cousin of the mother, who died of a heart attack before he could be examined. Two copies of the defective gene must be inherited for a person to lack the sensation of pain.

Because many genes and nerves are involved in mediating pain, it is surprising that a mutation in a single gene could inactivate the whole system. The reason, Dr. Woods said, is probably that a common mechanism is involved in all feelings of pain.

Nerve fibers have different proteins embedded in their endings, each of which is sensitive to a different kind of injury. These sensor proteins act by letting a few sodium ions flow into the nerve, though not enough to set off a pain signal. The proteins made by the SCN9A gene amplify the initial activity by letting a much larger number of sodium ions flow in, initiating an electrical signal that is interpreted as painful when it reaches the brain.

Presumably because all pain fibers depend on the SCN9A gene’s protein for amplification, all signals of pain are muted when the gene is inactive, Dr. Woods said.


From NYTimes.com


First  Previous  2 of 2  Next  Last 
Reply
 Message 2 of 2 in Discussion 
From: ReneSent: 2/28/2007 10:15 PM

 

Genetic Basis for Chronic Pain Conditions Discovered

ImmuneSupport.com, 01-10-2007

Study identifies “a new genetic mechanism that influences an individual's susceptibility to develop chronic pain conditions�?such as TMJD and Fibromyalgia

December 22, 2006 - CHAPEL HILL. Researchers at the University of North Carolina (UNC) at Chapel Hill have discovered that commonly occurring variations of a gene trigger a domino effect in chronic pain disorders. The finding [which kicks off a seven-year, $19 million NIH-funded research initiative*] might lead to more effective treatments for temporomandibular joint disorder (TMJD) and other chronic pain conditions.

Catechol-O-methyltransferase (COMT), an enzyme that metabolizes neurotransmitters such as epinephrine, norepinephrine, and dopamine �?and that has been implicated in the modulation of persistent pain, as well as cognition and mood �?is regulated by a gene, also called COMT. Previous UNC-led research showed that common genetic variants of this gene are associated with increased pain sensitivity and the likelihood of developing TMJD.

Now, the researchers have discovered that specific variants of the COMT gene can dramatically affect the secondary structure of corresponding messenger RNA - which, in turn, leads to alterations in the amount of enzyme crucial for regulating pain processing. The discovery was published in the December 22, 2006 issue of the journal Science.**

"TMJD is a complex pain condition that is frequently associated with other pain conditions such as Fibromyalgia Syndrome, chronic headaches, and Irritable Bowel Syndrome," said Dr. William Maixner, director of the Center for Neurosensory Disorders in UNC's School of Dentistry and a study co-author.

"This study has identified a new genetic mechanism that influences an individual's susceptibility to develop chronic pain conditions such as TMJD," Maixner said.

The study was conducted to understand the mechanism by which the identified genetic variants influence enzymatic activity and, ultimately, biological functions such as pain transmission. The researchers found that three major variants of COMT show significant differences in how they code for the secondary structure of messenger RNA, or mRNA. [mRNA mediates the transfer of genetic information from the cell nucleus to provide a template for protein synthesis.] The differences lead to dramatic alterations in protein expression, which substantially influences pain sensitivity in humans.

Implications for Diagnosis and Treatment
These findings are clinically important because pain conditions resulting from low COMT activity or elevated catecholamine levels are likely to be susceptible to treatment with pharmacological agents that block beta 2- and beta 3-adrenergic receptors, which mediate COMT-dependent pain signaling, or that control mRNA secondary structure.

"Elucidating the genetic mechanisms that mediate pain perception will provide new insights into how chronic pain develops and will ultimately contribute to the identification of unique markers for diagnosing clinical pain conditions, as well as provide novel targets for the development of effective individualized therapeutics for TMJD and related conditions," said Dr. Andrea Nackley Neely, a research assistant professor in the Center for Neurosensory Disorders and the study's lead author.

"These data have broad medical and evolutionary implications regarding the analysis of variants common in the human population," Nackley Neely said. "It is believed that variants leading to altered protein structure have the strongest impact on gene function. However, this study demonstrates that combinations of common genetic variants that influence mRNA secondary structure may have even stronger effects and, thus, represent another key factor responsible for disease onset and progression."

"This study provides additional evidence of a genetic, molecular and physiological basis for pain perception and human pain conditions and should help to remove the stigma associated with conditions such as TMJD and fibromyalgia," said Dr. Luda Diatchenko, an associate professor in the center and the study's chief investigator.


Other researchers were:

    • Dr. Inna Tchivileva, a postdoctoral research associate within the Center for Neurosensory Disorders;
    • Kathryn Satterfield, a former research assistant within the center;
    • Dr. Olex Korchynskyi, a former postdoctoral research associate within the UNC-Chapel Hill School of Medicine's Thurston Arthritis Research Center;
    • Dr. Sergei S. Makarov, a former associate professor at the Center for Neurosensory Disorders and the Thurston center and now president and chief executive officer of Attagene Inc.;
    • Dr. Svetlana A. Shabalina, a staff scientist with the National Center for Biotechnology Information.


Funding was provided by the National Institute of Dental and Craniofacial Research, National Institute of Child Health and Human Development and National Institute of Neurological Disorders and Stroke, all components of the National Institutes of Health. Additional support came from the Intramural Research Program of the National Center for Biotechnology Information.


Part One of $19 Million NIH-Funded Intiative

Other Center for Neurosensory Disorders research initiatives are currently under way that further explore the genetic basis of pain: [They continue a] seven-year, $19-million National Institute of Dental and Craniofacial Research-funded agreement involving multiple institutions and based at the center, and will follow 3,200 healthy individuals and 200 who have facial pain. Titled OPPERA (Orofacial Pain: Prospective Evaluation and Risk Assessment), the study is designed to identify both environmental and genetic factors that increase an individual's susceptibility to TMJD and other chronic pain conditions.

* See “NIDCR Launches Important Study on Temporomandibular Joint and Muscle Disorders,�?at http://www.immunesupport.com/library/showarticle.cfm/id/6886

** The article, titled “Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure,�?by AG Nackley, et al., was published in the December 22, 2006 issue of the journal Science. To view an abstract and supporting materials and methods, or to purchase the full text of the article, go to http://www.sciencemag.org/content/vol314/issue5807/index.dtl#r-articles